Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

<p><strong>Background</strong> Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enro...

Full description

Bibliographic Details
Main Authors:	Datoo, MS, Dicko, A, Tinto, H, Ouédraogo, J-B, Hamaluba, M, Olotu, A, Beaumont, E, Ramos Lopez, F, Natama, HM, Weston, S, Chemba, M, Compaore, YD, Issiaka, D, Salou, D, Some, AM, Omenda, S, Lawrie, A, Bejon, P, Rao, H, Chandramohan, D, Roberts, R, Bharati, S, Stockdale, L, Gairola, S, Greenwood, BM, Ewer, KJ, Bradley, J, Kulkarni, PS, Shaligram, U, Hill, AVS
Other Authors:	R21/Matrix-M Phase 3 Trial Group
Format:	Journal article
Language:	English
Published:	Elsevier 2024

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Similar Items